Internal Med

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Nordstrom, D.C., et al. - Fewer than 40% of newly diagnosed patients with rheumatoid arthritis (RA) reach remission with a combination of traditional DMARDs, and therefore new effective therapies are still needed. Proinflammatory cytokines, such as TNF-alpha and IL-1, are important pathogenetic mediators in RA and related conditions. Targeted therapies against these cytokines and downstream inflammatory mediators have greatly added to the therapeutic arsenal and brought new hope to patients in providing physicians with new effective treatment options


Today in Clinical Pharmacology...keeping you current

Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09

New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09

Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09

Today in Orthopedic/Physical Med...keeping you current

Osteoarthritis: A review of treatment options
Geriatrics, 10/21/09

Doxycycline for osteoarthritis of the knee or hip
Cochrane Reviews, 10/23/09

Bisphosphonate therapy: When not to monitor BMD
The Journal of Family Practice, 11/02/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address